- Home
- GOF vs AGIO Comparison
GOF vs AGIO Comparison
Compare GOF & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOF
- AGIO
- Stock Information
- Founded
- GOF 2006
- AGIO 2007
- Country
- GOF United States
- AGIO United States
- Employees
- GOF N/A
- AGIO N/A
- Industry
- GOF Finance/Investors Services
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- GOF Finance
- AGIO Health Care
- Exchange
- GOF Nasdaq
- AGIO Nasdaq
- Market Cap
- GOF 2.2B
- AGIO 2.0B
- IPO Year
- GOF N/A
- AGIO 2013
- Fundamental
- Price
- GOF $15.39
- AGIO $33.94
- Analyst Decision
- GOF
- AGIO Buy
- Analyst Count
- GOF 0
- AGIO 7
- Target Price
- GOF N/A
- AGIO $56.33
- AVG Volume (30 Days)
- GOF 789.2K
- AGIO 975.9K
- Earning Date
- GOF 01-01-0001
- AGIO 02-13-2025
- Dividend Yield
- GOF 15.42%
- AGIO N/A
- EPS Growth
- GOF N/A
- AGIO N/A
- EPS
- GOF N/A
- AGIO 11.80
- Revenue
- GOF N/A
- AGIO $32,871,000.00
- Revenue This Year
- GOF N/A
- AGIO $33.41
- Revenue Next Year
- GOF N/A
- AGIO $172.14
- P/E Ratio
- GOF N/A
- AGIO $2.78
- Revenue Growth
- GOF N/A
- AGIO 36.79
- 52 Week Low
- GOF $10.96
- AGIO $21.18
- 52 Week High
- GOF $16.76
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- GOF 50.60
- AGIO 38.43
- Support Level
- GOF $15.15
- AGIO $31.39
- Resistance Level
- GOF $15.36
- AGIO $35.03
- Average True Range (ATR)
- GOF 0.14
- AGIO 1.65
- MACD
- GOF 0.03
- AGIO 0.61
- Stochastic Oscillator
- GOF 64.87
- AGIO 48.05
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.